Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial

ConclusionsThe tolerable dose of sunitinib in chemotherapy-na ïve pediatric patients is at least 20 mg/m2 on schedule 4/2. The safety profile and PK of sunitinib in pediatric patients with GIST are comparable to those in adults.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research